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The epithelial sodium channel (ENaC) is responsible for Na+ and fluid absorption across 
colon, kidney and airway epithelia. Short Palate Lung and Nasal Epithelial Clone 1 (SPLUNC1) 
is a secreted, innate defense protein and an autocrine inhibitor of ENaC that is highly expressed 
in airway epithelia. While SPLUNC1 has a bactericidal permeability-increasing protein (BPI)-
type structure, its N-terminal region lacks structure.  Here we found that an eighteen amino acid 
peptide, S18, which corresponded to residues G22-A39 of SPLUNC1’s N-terminus inhibited 
ENaC activity to a similar degree as full-length SPLUNC1 (~2.5 fold), whilst SPLUNC1 protein 
lacking this region was without effect.  S18 did not inhibit the structurally related acid-sensing 
ion channels, indicating specificity for ENaC.  However, S18 preferentially bound to the β-ENaC 
subunit in a glycosylation dependent manner.  ENaC hyperactivity is contributory to cystic 
fibrosis (CF) lung disease.  Unlike control, CF human bronchial epithelial cultures (HBECs) 
where airway surface liquid height (ASL) was abnormally low (4.2 ± 0.6 µm), addition of S18 
prevented ENaC-led ASL hyperabsorption and maintained CF ASL height at 7.9 ± 0.6 µm,  even 
in the presence of neutrophil elastase, which is comparable to heights seen in normal HBECs.  
Our data also indicate that the ENaC inhibitory domain of SPLUNC1 may be cleaved away from 
the main molecule by neutrophil elastase, suggesting that it may still be active during 
inflammation or neutrophilia. Furthermore, the robust inhibition of ENaC by the S18 peptide 







The epithelial sodium channel (ENaC) is the apical conduit for Na+ absorption across a 
wide range of epithelia including renal, gastrointestinal and airway (22). The airway surface 
liquid (ASL) is composed of a mucus layer, which is responsible for trapping both inhaled 
particles and pathogens such as bacteria and a periciliary layer which facilitates ciliary beating 
and serves as a cell surface lubricant (32, 36).  Airway epithelia can both absorb Na+ through 
ENaC and secrete Cl- through the cystic fibrosis transmembrane conductance regulator (CFTR).  
A precise balance of Cl- secretion and Na+ absorption across the airway is critical for regulating 
ASL volume.  Normal human bronchial epithelial cultures (HBECs) regulate ASL height to an 
optimal depth of ~7 µm while cystic fibrosis (CF) HBECs consistently show a much lower depth 
of ~4 µm (32).  ENaC is negatively regulated by CFTR (44) and in CF patients, CFTR’s absence 
results in ENaC hyperactivity, leading to uncontrolled absorption of Na+ and ASL volume 
depletion which slows or abolishes mucus transport.  This lack of mucus transport leads to a 
failure to physically clear the lungs of accumulated mucus and inhaled pathogens and causes 
chronic lung infections which eventually leads to their destruction (40).   
ENaC is made up of three subunits, α, β, and γ, which share ~30% sequence homology 
(12).  Structurally, each subunit is made up of two transmembrane domains, short N- and C-
terminal cytoplasmic tails and a large extracellular loop which contains numerous sites for N-
linked glycosylation (11, 37).  Activation of this channel occurs through proteolytic cleavage of 
the extracellular loops of the α and γ ENaC subunits by furin-type convertases (14, 25), 
membrane bound channel activating proteases (CAPs), such as prostasin (CAP1) and TMPRSS4 
(CAP2)  and/or soluble proteases including the serine proteases trypsin and neutrophil elastase 
(39).   When these proteases are blocked by specific protease inhibitors, such as aprotinin for 
4 
 
trypsin-like proteases, ENaC activation is attenuated (8).  Alternatively, the cleaved segments of 
 and  ENaC may bind back into the channel and serve as inhibitory peptides (9, 13).  Little is 
known about the physiological regulation of these key ENaC proteolytic processes.  However, 
we recently hypothesized that a soluble modulator of ENaC existed in the ASL and designed a 
proteomic screen to identify it (20, 46).  Our data indicated that the short palate, lung and nasal 
epithelial clone 1 (SPLUNC1) was the soluble modulator of both ENaC activity and ASL 
volume and knockdown of SPLUNC1 abolished ENaC regulation in normal HBECs, leading to 
CF-like ASL volume depletion (20).  SPLUNC1 is endogenously secreted into the ASL and 
functions as an ASL volume sensor:  as ASL volume increases, SPLUNC1 becomes diluted, 
removing the inhibition of ENaC and signaling for absorption to begin; conversely, when ASL 
volume is low, SPLUNC1 is concentrated, causing less ENaC activity.    
SPLUNC1 is a 256 amino acid protein that belongs to the bactericidal permeability-
increasing (BPI)-fold containing family A and is also known as BPIFA1, LUNX, PLUNC and 
SPURT.  SPLUNC1 is expressed in the upper airways and nasopharyngeal regions and may also 
be expressed in Na+ absorbing tissues including the colon and kidney (20).  Based on sequence 
similarity with BPI-like proteins, SPLUNC1 was hypothesized to be an innate defense protein 
and indeed, SPLUNC1 has been shown to be both antimicrobial and to reduce surface tension (3, 
15, 19, 49).  More recently, SPLUNC1 has been proposed to be a multi-functional defense 
protein since its knockdown in vivo has been shown to decrease mucus clearance (33) as well as 
to increase Mycoplasma pneumoniae infection (19). Due to the wide variety of functions 
assigned to SPLUNC1, we set out to identify its ENaC inhibitory domain to better understand 




Oocyte studies.  Xenopus laevis oocytes were harvested and injected as previously described 
(18).  Oocytes were studied 24 h post-injection using the 2 electrode voltage clamp technique as 
previously described (20).  Where appropriate, oocytes were incubated with S18 or a control 
peptide, ADG, (described below) for 1 h prior to recording.  ENaC activity was determined by 
measuring the amiloride-sensitive current. In some experiments β-ENaCS518C was used, which 
forms ENaCs that are locked into a fully open state with an open probability near 1.0 by 
exposure to the sulfhydral reactive reagent, [2-(Trimethyl-
ammonium)ethyl]methanethiosulphonate bromide (MTSET).  MTSET was added at a 
concentration of 1 mM to the oocyte bath as previously described (43). Oocyte buffer solutions 
were used exactly as described previously (20).  
Peptides. Peptides were synthesized and purified by the UNC Microprotein Sequencing 
and Peptide Synthesis Facility. The sequence of the S18 peptide was: 
GGLPVPLDQTLPLNVNPA.  A control peptide of S18, ADG, was made by alphabetizing the 
sequence.  The sequence of ADG was: ADGGLLLLNNPPPPQTVV.  Both peptides were used 
with either a free or biotinylated N- terminus as needed. Biotinylation had no effect on S18’s 
ability to inhibit ENaC (n=6).  
Electrophysiological measurements of ASICs.  Previously described cell lines 
expressing human ASIC1a, human ASIC2a and rat ASIC3 were used in these experiments (34).  
Electrophysiological measurements were carried out with an EPC10 patch-clamp amplifier 
(HEKA Electronics, Lambrecht, Germany) as previously described (6).  
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Cell culture. HEK293T cells were cultured in DMEM/F12 medium containing 10% FBS, 
1x penicillin/streptomycin, 0.2 μg/mL puromycin, and 0.1 mM hygromycin at 37ºC/5% CO2 on 
6-well plastic plates. Cells were transfected according to the manufacturer’s instructions using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) using the DMEM/F12 media.  Cells were 
transfected when 90-95% confluent with 0.5 μg of plasmid DNA per construct per well and 
incubated at 37ºC/5% CO2 overnight.  CHO cell lines stably expressing human ASIC1a, human 
ASIC2a and rat ASIC3 were used in the electrophysiological measurements of ASICs (34). 
 
Human excess donor lungs and excised recipient lungs were obtained at the time of lung 
transplantation and cells were harvested by enzymatic digestion as previously described under a 
protocol approved by the UNC Institutional Review Board (46). HBECs were maintained at an 
air-liquid interface in a modified bronchial epithelial growth medium (BEGM) with 5% CO2 at 
37ºC and used 2-5 weeks after seeding on 12-mm T-clear inserts (Corning-Costar, Corning, NY, 
USA) (35).   For experiments performed out of the incubator, both HEK293T cells and HBECs 
were maintained in a modified Ringer solution as described previously (20).  
Peptide pull-down assay and western blotting. HEK293T cells were plated in standard 
plastic 6 well plates (Corning Costar) transfected with double-tagged human ENaC subunits with 
HA and V5 epitopes at the N- and C- termini, respectively, in combination with wild-type 
untagged subunit cDNA when 90% confluent.   When all three ENaC subunits were expressed, 
0.5 μg of each subunit were transfected.  When expressed individually, 0.75 μg of the subunit 
was transfected. The transfected cells were lysed 24 h later using NP-40 buffer with 1x complete 
EDTA-free protease inhibitor (Roche, Basel, Switzerland). The lysate was centrifuged at 16,300 
x g for 15 min at 4ºC and the supernatant collected.  Protein concentration was determined using 
7 
 
the BCA assay  and 500 μg of protein plus 0.25 mg peptide and 100 μL of neutravidin were 
added to a spin column and rotated end-over-end at 4ºC for 24 h (all ThermoFisher Scientific, 
Rockford, IL, USA).  Flow-through was collected by centrifugation at 1000 x g for 30 s.  The 
beads were then washed 5 times with NP-40 buffer.  Bound protein was eluted by boiling at 95ºC 
for 10 minutes in 75 μL of 2 times LDS NuPAGE sample buffer with 1x sample reducing agent 
followed by centrifugation at 16,300 times g for 2 min.  Samples were resolved on 4-12% Bis-
Tris gels in MES and transferred to a nitrocellulose membrane using iBlot, setting P3 for 8 min 
(Invitrogen, Carlsbad, CA, USA).  The membrane was probed using 1:1000 anti-V5 antibody 
(Invitrogen, Carlsbad, CA, USA) overnight at 4ºC in 3% fish gelatin in TBS-T.  The blot was 
then incubated for 1 h at room temperature with an ECL sheep anti-mouse IgG secondary 
antibody and detected by ECL reagent (ThermoFisher Scientific, Waltham, MA, USA) or by 
incubation with a goat anti-mouse IRDye secondary antibody and analyzed by an Odyssey 
infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA). Pull-down was performed 
using an N-terminally biotinylated version of S18 or ADG.  Biotinylation had no effect on the 
ability of S18 to inhibit ENaC (n=12).  
Deglycosylation. Peptide pull-down assays were performed as described above. Samples 
were eluted by the addition of 100 μL of 0.1 M sodium citrate, pH 5.5, 0.1% SDS to the beads 
and incubating at 100ºC for 2 min, followed by centrifugation at 16,300 x g for 2 minutes.  The 
samples were divided equally, and one half was treated with 1 μL of EndoH and incubated at 
37ºC for 2 min.  After incubation, all samples were lyophilized and then reconstituted in 30 L 
LDS NuPAGE sample buffer with 1x sample reducing agent (Invitrogen, Carlsbad, CA, USA).  
Western blots were completed as described above.  A concentration of 5 μg/ml tunicamycin 
(Sigma-Aldrich, St Louis, MO, USA) was added to the cell transfection media and the cells were 
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incubated overnight at 37ºC/5% CO2.  The following day the protocol for the peptide pull-down 
assay was performed as described above. 
ASL height measurements. To label the ASL, 20 μl PBS containing 10 kDa Rhodamine 
dextran (0.2-2 mg/mL; Invitrogen, Carlsbad, CA, USA) was added to HBEC mucosal surfaces as 
previously described (45). When added, peptides with or without 100 nM neutrophil elastase, 1 
U/mL aprotinin, activated neutrophil supernatant (ANS) (23) or 10 μM sivelestat (Sigma-
Aldrich, St Louis, MO, USA) were added to the mucosal surface along with the Rhodamine 
dextran.  In some cases, bumetanide (100 μM) was added to the serosal solutions for the duration 
of the experiment. The HBEC mucosal surfaces were washed with 500 μL PBS for 30 min prior 
to experimentation to remove accumulated endogenous SPLUNC1.  SPLUNC1 recovery into the 
ASL was measured over time by lavaging with 200 μL PBS at timed intervals after the initial 
wash/volume load. To detect SPLUNC1, 20% by volume of the lavage was transferred onto a 
nitrocellulose membrane using a slot blot apparatus (GE Healthcare, USA).  The blot was 
processed as described above using an anti-hPLUNC primary antibody (R & D Systems, 
Minneapolis, MN, USA). 
Transepithelial potential difference (Vt) studies. A single-barreled Vt-sensing electrode 
was positioned in the ASL by micromanipulator and used in conjunction with a macroelectrode 
in the serosal solution to measure Vt using a voltmeter (World Precision Instruments, Sarasota, 
FL, USA) as described (20).   Bumetanide (100 M) was present for all measurements to inhibit 
Vt due to Cl
- secretion.  To calculate the amiloride-sensitive Vt, Vt was measured, amiloride was 
added as a dry powder in perfluorocarbon and Vt was remeasured 10 min later. Thus, the 
amiloride-sensitive Vt constitutes the difference between these values.  
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Circular dichroism (CD). 100 µM S18 was dissolved in a buffer containing 10 mM 
sodium phosphate, pH 7.4 in a 1 mm cuvette. Using a Chirascan-plus instrument (Applied 
Photophysics Limited, Leatherhead, UK), five individual spectra from 185 to 280 nm were 
recorded at 25 ± 1.0°C and averaged.  All measurements were corrected for buffer signal.  
Expression and Purification of Human SPLUNC1.  Full-length SPLUNC1 cDNA was 
kindly provided by Dr. Colin Bingle.  The SPLUNC1-Δ19 and Δ44 constructs were created by 
cloning amino acid residues 20–256 or 45-256 out of the SPLUNC1 cDNA for entry into 
pMCSG7 for protein expression. BL21-CodonPlus competent cells (Agilent Technologies, Santa 
Clara, CA, USA) were transformed with the expression plasmid and cultured in the presence of 
antifoam (50 L), ampicillin (100 g/mL) and chloramphenicol (34 g/mL) in LB medium with 
vigorous shaking at 37°C until an OD600 of 0.6 was attained. Expression was induced with the 
addition of isopropyl-1-thio-D-galactopyranoside (IPTG). Bacteria were collected by 
centrifugation at 4500 x g for 20 min at 4°C. Cell pellets were rsuspended in Buffer A (20 mM 
Potassium Phosphate, pH 7.4, 50 mM Imidazole, 500 mM NaCl and 0.02% NaAzide) along with 
lysozyme, DNase1, and protease inhibitor tablets. Cells were sonicated and cell lysate was 
separated into soluble and insoluble fractions using high-speed centrifugation. The soluble 
fraction was filtered then flowed over a Ni-NTA His-Trap gravity column and washed with 
Buffer A. The bound protein was eluted with Buffer B (20 mM Potassium Phosphate, pH 7.4, 
500 mM Imidazole, 500 mM NaCl and 0.02% NaAzide) and separated using an S200 gel 
filtration column on an ÄKTAxpress™. The C-terminal histidine tag was removed with Tev 
protease as described before experimentation (21). Another round of nickel and HPLC 
purification removed the tag from the purified SPLUNC1-Δ19. We confirmed that SPLUNC1-
Δ19 purified in this fashion inhibited ENaC in CF airways (n=6). 
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Neutrophil elastase cleavage of SPLUNC1-Δ19 and analysis by LC-ESI/MS/MS. 
Neutrophil elastase was added to SPLUNC1-Δ19 at a ratio of 1:1000 (enzyme: protein) followed 
by incubation for 5, 15 and 60 min at 37°C.  Digested samples (5 μL) were introduced to a Q-Tof 
micro mass spectrometer (Waters, Manchester, UK) via a nano-acquity UPLC (Waters, Milford 
MA, USA) system as described previously (31). Briefly, the analytical system was configured 
with a PepMapTM C18 (LC Packing, 300µm ID x 5mm) pre-concentration column in series with 
an Atlantis® (Waters) dC18 NanoEaseTM (75 m x 150 mm) nanoscale analytical column. Peptides 
were separated on the column with a gradient of 5% acetonitrile in 0.1% formic acid to 60 % 
acetonitrile in 0.1% formic acid over 60 min and were directly analyzed without addition trypsin 
digestion. All data were acquired using MassLynx 4.1 software. The raw data acquired were 
processed using the ProteinLynx module of MassLynx 4.1 to produce *.pkl (peaklist) files which 
are suitable for the MS/MS ions database search via search engines. The data processed was 
searched against the Uniprot protein database (release 2011_09) using an in house MASCOT 
(Matrix Science, London, UK) search engine (Version 2.2). MASCOT probability based Mowse 
individual ion scores > 40 were accepted as indicating identity or extensive homology (p<0.05).  
SPLUNC1 peptides in CF patients and donor sputum.  Human sputum samples were 
obtained as previously described (30).  The study protocol was approved by the University of 
North Carolina Committee on the Protection of Rights of Human Subjects, and informed consent 
was obtained.   Sputum from 4 CF patients and 4 healthy donors were pooled, respectively. 1 mL 
of pooled sputum from each group was diluted in 4 mL PBS. The samples were filtered through 
a 0.22 µm membrane (Millipore, Bedford, MA). The resulting filtrate were injected onto an 
Ettan LC chromatographic system (Amersham Pharmacia Biotech, Piscataway, NJ) with a 
Superdex 200 HR 10/30 chromatography column.  The large proteins were separated from the 
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low-molecular-weight peptides with PBS elution at a flow rate of 0.3 mL/min.  The peptide pool 
was dried down 10x by volume using a vacuum concentrator and then mixed 1:1 with 1% formic 
acid and subjected to nano-LC-electrospray ionization-tandem MS (MS/MS) and analyzed using 
the above parameters. N.B., unlike conventional proteomic studies, the sputum samples were not 
trypsin-digested and only peptides that were endogenously formed were detected while all other 
protein was excluded from the analysis.  
Statistical analyses. Unless otherwise noted, all data are presented as means ± se for n 
experiments. Differences between means were tested for statistical significance using paired or 
unpaired t tests when the variances were homogeneously distributed, or in the case of 
nonhomogeneity of variance, the Wilcoxon rank-sum or Mann-Whitney U tests were used as 
appropriate. From such comparisons, differences yielding values of P < 0.05 were judged to be 
significant. HBECs derived from >3 donors were used per experiment, and experiments using 
cell lines were repeated on 3 separate occasions. All analyses were conducted using Instat 
software (GraphPad, San Diego, CA, USA). 
RESULTS 
Identification of SPLUNC1’s ENaC inhibitory domain.  
SPLUNC1 is a 256 amino acid protein that has a cleavable N-terminal signal sequence.  
We have recently resolved the crystal structure of SPLUNC1 lacking this signal sequence (19-
SPLUNC1) (21). Interestingly, the N-terminal region up to residue 43 was different from the rest 
of SPLUNC1 in that it lacked any discernible structure.  However, a peptide, termed S18, which 
corresponded to this unstructured N-terminal region of SPLUNC1 
(22GGLPVPLDQTLPLNVNPA39), prevented cleavage of ENaC in HBECs derived from both 
normal and CF subjects (21).  To examine the effects of S18 on HBECs in more detail, we first 
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examined its onset of action.  Inhibition of ENaC can cause hyperpolarization of the apical 
membrane and increase the transepithelial voltage (Vt) caused by Cl
- secretion (24). Thus, we 
exposed HBECs to serosal bumetanide to inhibit Cl- secretion before measuring Vt, since under 
these conditions, the remainder of Vt is largely due to ENaC activity/Na
+ absorption (Fig. 1A). 
The S18 peptide significantly inhibited the bumetanide-insensitive Vt in normal HBECs in a 
similar time as SPLUNC119, whilst an alphabetized version of S18 (ADG, control) was without 
effect. Furthermore, amiloride strongly inhibited Vt in ADG- and vehicle- treated but not S18- or 
SPLUNC1-treated cultures.   When added mucosally for 1 h, both S18 and SPLUNC119 both 
inhibited the amiloride-sensitive Vt.  In contrast, 44-SPLUNC1, which lacks the S18 region 
(i.e. amino acids G22-A39) had no significant effect, suggesting that SPLUNC1’s ENaC 
inhibitory domain was located at the N-terminus of SPLUNC1 (Figure 1B).  
To confirm that S18 was acting on ENaC, we co-injected oocytes with α, βS518C, γ ENaC 
subunits and incubated them with 10 or 100 µM S18 for 1 h. We subsequently observed an ~2.5 
fold decrease in INA (p < 0.05), indicating that we had identified the ENaC inhibitory domain of 
SPLUNC1 (Figure 2A). To further explore the effects of S18, MTSET was added during 
recording to lock the channel into a fully open position and give an approximation of the number 
of active channels in the plasma membrane (38, 43).  MTSET significantly increased ENaC 
activity ~6 fold over basal current levels (Figure 2B). In the presence of S18, MTSET still raised 
INA above basal levels. However, the increase was significantly less than under control 
conditions, suggesting that exposure to S18 resulted in a decrease in surface ENaC levels (Figure 
2B).  In contrast, when incubated with the control peptide, ADG, no difference in the INA was 
observed (Figure 2C).   
Structurally related acid-sensing ion channels (ASICs) are not inhibited by S18.  
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We tested whether SPLUNC1 affected the function of the related ENaC/degenerin family 
members, the acid-sensing ion channels (ASICs).  In order to assess possible effects of S18 on 
the pH dependence of ASIC activation and on current amplitude, channels were activated by a 
change from pH 7.4 to a pH corresponding to the steep phase of their activation curve, pH 6.6 for 
ASIC1a and -3, and 4.0 for ASIC2a.  At these stimulation pH values, a change in current 
expression or pH dependence would be readily detected as a change in the measured current 
amplitude. Stimulations of 5 s duration were performed every 45 s to allow recovery from 
inactivation between stimulations. Three control values were obtained before switching to a pH 
7.4 solution containing 10 M S18. The S18 peptide was then present during 3 stimulation 
rounds in both the conditioning (pH 7.4) and the acidic stimulation solution before it was washed 
out.  Figure 3A illustrates a typical experiment with an ASIC1a-expressing cell. Average current 
amplitudes were normalized to the first control value and plotted as a function of time (Figure 
3B). The peptide had no apparent effect on the activation properties of the different ASICs tested 
(n=3 by channel type, p>0.05). No changes in current kinetics were observed (not shown).  
When exposed to a pH that is less than pH 7.4, but is insufficiently acidic to activate the channel, 
ASICs inactivate directly from the closed state.  This process is known as steady-state 
inactivation (SSI).  Its pH dependence has been determined to have a midpoint of pH 7.2 for 
ASIC1a, pH 7.1 for ASIC3 and 5.6 for ASIC2a (6). To detect changes in the pH dependence of 
SSI due to the presence of the peptide, cells were incubated 40 s in a conditioning solution with a 
pH close to the midpoint of SSI, in the presence or absence of the peptide (7.1 for ASIC1a, and -
3, pH 5.6 for ASIC2a). The conditioning period was followed by activation with an acidic 
stimulus (pH 6.0 for ASIC1a and -3 and pH 4 for ASIC2a). Figure 3C plots the average values of 
the current after the conditioning period normalized to the maximal current obtained with a 
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conditioning pH of 7.4. The peptide does not modify the pH dependence of steady-state 
inactivation of the tested ASICs.  
Cleavage of ASIC1a channels by trypsin leads to a shift in the pH dependence of 
activation to more acidic values (34). ASIC1a was first activated three times by pH 6.6, every 45 
s. The conditioning solution was then switched to a pH 7.4 solution containing 40 g/ml trypsin 
with or without 10 M S18, and currents were measured every 45 s at pH 6.6. Due to the trypsin-
elicited time-dependent shift in the pH dependence of activation, we observed a gradual 
reduction in pH 6.6-evoked current in the presence of trypsin, as illustrated in Figure 3D. This 
current decrease was not prevented by S18.  
 Since S18 takes up to one hour to fully inhibit ENaC (Figure 1A), we then pre-exposed 
ASICs to S18 for 1 h before performing patch clamp studies.  This maneuver had no effect on 
ASIC1a or ASIC3 current densities (Figure 4).  However, ASIC2a was significantly activated by 
this 1 h pretreatment (Figure 4).  
S18 may interact through the β-ENaC subunit.  
Using co-immunoprecipitation, we have previously demonstrated that SPLUNC1 binds to 
αβγ-ENaC (20).  A pull-down assay was performed using biotin-labeled S18 to determine if the 
peptide was also able to interact with ENaC in a similar fashion.  Three different transfections 
were performed with one of the three subunits V5-tagged and the other two untagged.  The cell 
lysates were then incubated with biotinylated S18 bound to neutravidin beads.  As observed with 
full-length SPLUNC1, S18 was found to pull-down all three ENaC subunits, although ENaC 
was more strongly pulled down than either - or - ENaC (Figure 5A).  To further characterize 
this interaction, each subunit was expressed individually and the pull-down assay repeated.  In 
this case, only β-ENaC was detected in the elution, suggesting that under these conditions, S18 
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binds exclusively to the β-ENaC subunit and not to the α- or γ- subunits (Figure 5B).  When the 
pull-down assay of the β-ENaC subunit was performed with ADG, β-ENaC was not detected in 
the elution, confirming that S18 is specifically binding to the β-ENaC subunit (Figure 5C). 
β-ENaC glycosylation is required for the β-ENaC/S18 interaction.  
The predicted molecular weight of a non-glycosylated β-ENaC subunit is ~73 kDa.  
However, the extracellular loop of β-ENaC contains 12 possible sites for N-linked glycosylation 
and β-ENaC is typically observed at 94-96 kDa due to extensive N-linked glycosylation (25).  As 
seen in Figure 5, the molecular weight of the β-ENaC subunit which predominantly interacted 
with the S18 peptide was around 94 kDa.  To confirm that this was glycosylated β-ENaC, the 
elution of the S18/α,βV5,γ ENaC pull-downs were deglycosylated with Endoglycosidase H 
(EndoH) (Figure 6A).  As previously described (25), upon treatment with EndoH, the 94 kDa β-
ENaC band shifted to ~73 kDa, consistent with the deglycosylation of β-ENaC (Figure 6A).  
This experiment was repeated with the βV5-ENaC subunit expressed alone.  Upon EndoH 
treatment, this band shifted to ~73 kDa (Figure 6B). EndoH treatment could only be performed 
once the pull-down assay had been completed;  therefore, to test whether S18 was able to interact 
with non-glycosylated β-ENaC, we exposed cells expressing either V5ENaC or V5ENaC to 
tunicamycin, an inhibitor of N-linked glycosylation (48).  The pull-down assay was then 
performed on the tunicamycin-treated cell lysate (Figures 6C, D).  As seen in the input lanes, 
treatment with tunicamycin reduced the molecular weight of the β-ENaC subunit to ~73 kDa, 
confirming that the protein was deglycosylated.  No β-ENaC was observed in the elution of the 
tunicamycin treated pull-downs (Figures 6C, D).  Combined with the EndoH data, these data 
indicate that S18 is interacting with a specific, glycosylated form of β-ENaC.   
S18 attenuates ASL hyperabsorption in CF HBECs through ENaC inhibition.  
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 To determine if S18 was capable of inhibiting ENaC dependent ASL absorption in native 
airway epithelia, we measured ASL height over time in both normal and CF HBECs after 
treatment with S18 (Figure 7A, B).  SPLUNC1 is endogenously secreted by both normal and CF 
HBECs, which could affect ASL volume regulation, especially in normal HBECs (20).  Thus, we 
standardized the mucosal washing/volume-loading protocol accordingly so that every culture had 
endogenous SPLUNC removed prior to t=0.  Each culture was left with undisturbed ASL for 24 
h. They were then incubated for 30 min with 500 μL PBS followed by two quick successive 
washes with 500 μL PBS. Then, 20 μL of PBS containing rhodamine-dextran was added as a 
volume challenge with or without peptide.  Slot-blot analysis revealed that it took 24 h for 
SPLUNC1 levels in the ASL to recover to baseline values (Figure 7B, inset).  Vehicle-treated CF 
HBECs had a significantly lower ASL height than normal controls.  However, the ASL height in 
CF S18 treated samples, 7.9 ± 0.6 µm, was significantly higher than the CF controls, 4.2 ± 0.6 
µm.  This increase in ASL height in S18 exposed CF HBECs was comparable to that observed in 
normal HBECs (~8 µm).  Next, a full dose response was completed in order to calculate the IC50 
by measuring the ASL height of both normal and CF HBECs 6 h after addition of S18 (Figure 
7C).  The IC50 was not significantly different between normal and CF HBECs, 0.29 ± 0.19 µM 
and 0.52 ± 0.23 µM, respectively.  
To test whether S18 specifically affected ENaC in normal and CF HBECs, the 24 h 
transepithelial potential difference (Vt) was measured (Figure 7D,E).  In the normal HBECs, a 
basal Vt of -6.6 ± 0.5 mV was observed and this decreased to -10.6 ± 0.7 mV following a brief 
exposure to trypsin, which is indicative of ENaC activation (46). S18 had little additional effect 
on the 24 h Vt in normal HBECs.  Consistent with our previous observation that CF ENaC 
remains fully active and non-responsive to trypsin (46), the CF vehicle-exposed HBECs had an 
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elevated Vt of -15.2 ± 0.9 mV and trypsin had no further effect.  In contrast, after 24 h exposure 
to S18, the CF HBEC Vt was significantly lowered to -8.4 ± 0.9 mV, and a 30 min exposure to 
trypsin changed the Vt to -11 ± 0.7 mV, suggesting that S18 works through ENaC in CF HBECs.  
In contrast, ADG had no effect on normal or CF HBEC Vt (both n=6).  To further confirm that 
S18 functions by inhibiting ENaC hyperabsorption, the ASL height of normal HBECs was 
measured over time in the presence of bumetanide with or without S18 (Figure 7F).  Serosal 
bumetanide significantly decreased normal ASL height toward CF levels (i.e. <5 μm).  In 
contrast S18 was able to maintain significantly greater ASL height even in the presence of 
bumetanide, indicating that S18 increases ASL height by inhibiting absorption not secretion. 
 
S18 has no intrinsic structure.  
 To better understand how S18 may interact with ENaC, we next looked for intrinsic 
structure in this peptide.  Since the S18 regions does not show up in the crystal structure of 
SPLUNC1 (21), we next used the program PSIPRED to predict its structure (10, 26).  No 
structure was predicted with PSIPRED and we also failed to detect any secondary structure by 
circular dichroism (Figure 8A).  To functionally test this hypothesis, we heat denatured S18 by 
incubating it at 67°C for 30 min, added it to the mucosal surface of CF HBECs and then 
measured ASL height 2 h later.  The heat denatured S18 was able to prevent ASL 
hyperabsorption to the same extent as the non-heat denatured peptide (Figure 8B), suggesting 
that S18 performs its function with no intrinsic secondary structure. 
S18 prevents CF ASL hyperabsorption in the presence of neutrophil elastase.  
CF airways are characterized by chronic neutrophilia and display a significantly higher 
level of neutrophil elastase activity than normal airways (47).  Since neutrophil elastase has 
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previously been shown to activate ENaC by cleaving the γ subunit (39), we tested whether S18 
was still capable of inhibiting CF ASL hyperabsorption in the presence of this protease (Figure 
9A).  Mucosal addition of S18, but not ADG, to CF HBECs resulted in a significant increase in 
ASL height.  Similarly, aprotinin which blocks trypsin-like proteases, was also able to maintain 
ASL height to a similar degree as S18.  Interestingly, S18 maintained its ability to prevent CF 
ASL hyperabsorption in the presence of neutrophil elastase, while aprotinin was unable to 
prevent neutrophil elastase induced ASL height depletion.  Activated neutrophil supernatant 
(ANS), which is derived from human neutrophils, contains high levels of neutrophil elastase 
activity (23), but did not diminish S18’s ability to prevent CF ASL volume hyperabsorption.  
When the neutrophil elastase inhibitor sivelestat, also known as ONO-5046, was added to the 
ASL along with S18 and NE, no further effect on ASL height was observed (Figure 8B).  
Together these data suggest that S18 may be able to prevent ASL hyperabsorption, even in the 
presence of the high proteolytic activity that is typically present in diseased CF lungs.   
Cleavage of SPLUNC1 by neutrophil elastase.  
To determine whether peptides corresponding to the N-terminal ENaC inhibitory domain 
of SPLUNC1 may be released from the main molecule by neutrophil elastase, the SPLUNC1-
Δ19 recombinant protein which lacks the N-terminal signaling sequence but contains the ENaC 
inhibitory domain was exposed to neutrophil elastase for 5, 15 and 60 min and the resulting 
cleavage products determined by mass spectrometry.  Similar sequence coverage was observed 
at all three time points ~80% (Figure 9C, Table 1).  Three peptides were observed by mass 
spectrometry that spanned the ENaC inhibitory domain (i.e. residues 23-45) at all three time 
points:  two ions corresponding to peptide 23GLPVPLDQTLPLNVNPALPLSPT45 with a m/z of 
1183.742+ and 789.493+ were observed; two ions corresponding to peptide 
19 
 
27PLDQTLPLNVNPALPLSPT45 with a m/z of 1000.592+ and 667.393+ were observed and one 
ion corresponding to peptide 32LPLNVNPALPLSPT45 with a m/z of 723.412+ was observed.  In 
addition to this, in the 15 and 60 min samples one ion corresponding to peptide 
20QFGGLPVPLDQTLPL34 with a m/z of 797.992+ was observed.  Several other peptides 
spanning this region were observed in the 60 min sample only including an ion corresponding to 
peptide 23GLPVPLDQTLPLNVNPA39 with a m/z of 879.532+.  All peptides observed in the 5 
min sample are listed in Table 1.   
Next, we determined which, if any, SPLUNC1 peptides were present in human sputum.  
In sputum obtained from normal subjects, four peptides were observed that spanned the ENaC 
inhibitory domain: an ion corresponding to peptide 28LDQTLPLNVNPALPLSPT45 with a m/z of 
952.032+, one ion corresponding to peptide 29DQTLPLNVNPALPLSPT45 with a m/z of 895.49+, 
one ion corresponding to peptide 32LPLNVNPALPLSPT45 with a m/z of 723.412+ and one ion 
corresponding to peptide 35NVNPALPLSPT45 with a m/z of 561.812+ were observed.  
Surprisingly, no peptides were observed in CF sputum before residue 46, consistent with our 






We have recently resolved SPLUNC1’s structure to 2.8 Å (21). As expected, SPLUNC1 
displays the a "half boomerang” shape that is typical of the bactericidal permeability-increasing 
protein/lipopolysaccharide-binding protein (BPI/LBP) superfamily (4).  In contrast, the N-
terminal domain (residues 20-43) had no observable structure.  Surprisingly, we found that a 
peptide which reprised this unstructured region, S18 (Residues G22-A39), inhibited ENaC to the 
same extent as 19-SPLUNC1, whilst SPLUNC1 lacking the S18 region (44-SPLUNC1) was 
without effect (Figure 1A, B).  We have previously shown that SPLUNC1 lowers ENaC surface 
densities (38). Since S18 and SPLUNC1 act over a similar time-frame, it is possible that S18 also 
reduces plasma membrane ENaC levels, rather than acting as a rapid-onset, amiloride-like pore 
blocker.   
In the presence of MTSET, S18 caused a significant decrease in ENaC activity.  We have 
assumed the MTSET has its usual effect in our study, i.e., to increase ENaC Po to ~1.0 (1).  One 
can divide the MTSET current by the basal current to give estimate the degree of activation by 
MTSET.  Due to the depression of basal currents, MTSET activation was significantly greater in 
the presence of S18 than in its absence (9 fold vs. 5.7 fold respectively).  This ratio has 
previously been taken as an indicator of channel open probability (Po) and the higher fold 
increase may indicate that ENaC resides in a lower Po in the presence of S18 (Figure 2) (1). 
Therefore, while it is likely that S18 decreases N, we cannot exclude the possibility that S18 may 
also have an additional effect on Po. Thus, an S18-induced reduction in MTSET-activated ENaC 
currents is consistent with S18 predominantly affecting N.  However, absent single channel data, 
which is not available to us at present, the possibility that S18 also affects Po still remains to be 
tested.   
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Despite being structurally related to ENaC, our experiments did not show any inhibitory 
effect of S18 on ASIC activity following either acute or 1 h exposure to this peptide (Figures 3, 
4). In the absence of an endogenous regulation of ASICs by proteases in the cell system used 
(34), a long-term exposure to S18 was not expected to have an effect.  However, we did find that 
the 1 h exposure to S18 significantly activated ASIC2a.  ASICs are the target of peptide toxins 
and of short peptides and several small, charged peptides have been shown to acutely modulate 
ASIC function (2, 42). Currently there is no evidence of endogenous regulation of ASICs by 
proteases, although it is known that ASIC1 pH dependence is changed by exposure to serine 
proteases (34). The inhibitory toxins and the inactivation-modifying peptides all contain Arg 
and/or Lys residues that appear to be important for their function (2, 17), while the S18 peptide 
does not contain Arg or Lys residues. As a caveat, since the experiments were performed with 
the S18 peptide, we cannot exclude the possibility that other parts of SPLUNC1 might still 
interact with ASICs.  
We found that S18 is able to pull down all three ENaC subunits when they are co-
expressed (Figure 5A).  However, when each subunit was expressed individually, only the β-
ENaC subunit was pulled down (Figure 5B,C).  These data suggest that a complex may form 
between the α, β, and γ ENaC subunits that is pulled down along with ENaC-S18.  
Alternatively, it may be possible that when co-expressed, parts of the α and γ ENaC extracellular 
domains may fold into a different conformation which is conducive to α and γ ENaC binding to 
S18 when β-ENaC is present.  
The predominant band observed in the peptide pull-down assay for β-ENaC, both when 
all three subunits were co-expressed, and when only the β-ENaC subunit was expressed, was ~94 
kDa (Figure 6A, B), which corresponds to glycosylated β-ENaC (25). In contrast, the expected 
22 
 
molecular weight for non-glycosylated β-ENaC is ~73 kDa.  When we pulled down -ENaC and 
exposed the elution to EndoH, the 94 kDa β-ENaC band pulled down with S18 was shifted to 
~73 kDa, indicating that the form of β-ENaC binding to the S18 peptide is glycosylated with 
non-complex, high mannose N-glycans (Figure 6A,B).   To confirm this interaction, cells were 
grown and transfected in the presence of tunicamycin, which prevents N-linked glycosylation.  
Under these conditions, S18 was unable to pull-down the non-glycosylated (i.e. tunicamycin-
sensitive) form of β-ENaC (Figure 6C-D). Whilst we cannot exclude the possibility that 
tunicamycin pretreatment caused mis-folding of the ENaC protein, leading to altered S18 
binding, taken together, our data lead us to conclude that the S18/ β-ENaC interaction is strongly 
dependent on the glycosylation state of β-ENaC.   
In addition to inhibiting ENaC in oocytes, S18, but not the control peptide ADG, was also 
capable of reducing ASL absorption and over a period of 24 h, S18 restored ASL height in CF 
HBECs to ~8 µm, which is comparable to that observed in normal HBECs (Figures 7A, B).  The 
transepithelial voltage (Vt) was measured in these same cultures to confirm that S18 was in fact 
functioning by inhibiting ENaC (Figure 7D, E).  The thin film Vt reflects a bumetanide -sensitive 
component (Cl- secretion through CFTR) and an amiloride/trypsin sensitive component (Na+ 
absorption through ENaC) (46).  In normal HBECs, the bumetanide-sensitive Vt is stable with 
time, while the trypsin-sensitive component changes with time as ENaC is inactivated by 
SPLUNC1 (20, 46).  In contrast, in CF HBECs there is no bumetanide-sensitive Vt due to the 
lack of CFTR and these cultures are also insensitive to trypsin, unless pretreated with a protease 
inhibitor like aprotinin since ENaC is not spontaneously regulated (46).  However, in both 
normal and CF HBECs, S18 caused a decrease in the 24 h Vt and in CF HBECs, induced trypsin 
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sensitivity, giving further evidence that S18 is acting through ENaC. Together these data indicate 
that S18 can serve to restore the regulation of ENaC that is lacking in CF HBECs.  
S18 is located at the N-terminus of SPLUNC1 in a region that is intrinsically disordered. 
Using circular dichroism, we demonstrated that the synthesized S18 peptide also displayed no 
secondary structure (Figure 8A).  This lack of secondary structure was further confirmed by the 
observation that heat-denatured S18 still prevented ASL hyperabsorption in CF HBECs (Figure 
8B). Other investigators have recently shown that unstructured regions of proteins play an 
important role in protein:protein interactions and that their flexibility is essential to their function 
(7).  It is also possible that the several proline residues followed by a hydrophobic residue in the 
S18 sequence are important for its function.  Proline-rich motifs have been recognized to play an 
important role in protein:protein interactions (29) and the role of the prolines, as well as the other 
residues, in S18 are currently being explored to further characterize and optimize its inhibitory 
function. 
Carattino et al. previously identified a 26 amino acid peptide that is excised from the α-
ENaC subunit during proteolytic processing, residues D206-R231 (14). When these residues are 
added back to cleaved ENaC they inhibit ENaC activity (14).  This 26-mer was further refined to 
a region of eight amino acids, residues L211-L218 (13).  Both the 26-mer and 8-mer α-ENaC 
peptides caused a reduction in the NPo of ENaC and they concluded that the reduction largely 
reflects a change in channel Po (13, 14, 27).  Interestingly, the sequence of the 8-mer, 
LPHPLQRL, shares 50% sequence identity with residues L24 to T31 (LPVPLDQT) of the S18 
peptide. However, the IC50 of the 8-mer was calculated to be 106 μM and 76 μM in normal and 
CF HBECs, respectively, which was much higher than the S18 peptide (0.29 µM and 0.52 µM in 
normal and CF HBECs, respectively).  The difference in the IC50s could be due to the 
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peptide:ENaC subunit interaction and the α-ENaC 8-mer is thought to bind to residues within the 
finger and thumb domains of α-ENaC (28), while our data show that S18 targets the β-ENaC 
subunit.  Further characterization of the S18 sequence will be needed to distinguish which 
residues play the largest role in the SPLUNC1 ENaC inhibitory domain.   
High levels of proteolytic activity are typically present in the diseased CF lung, leading to 
potential protein degradation by neutrophil elastase.  In the case of S18, this could lead to 
decreased efficacy and/or duration of action.  However, a single dose of S18 prevented CF ASL 
hyperabsorption over a 24 h period (Figure 7A) and was unaffected by either purified neutrophil 
elastase or activated neutrophil supernatant (Figure 9A).  The ability of S18 to function in a 
proteolytically active environment makes S18 a strong therapeutic candidate for restoring ASL 
height in CF patients.  Since S18 activity was unaffected by neutrophil elastase, we speculated 
that a region corresponding to this peptide may be released from SPLUNC1 upon proteolysis.  
MS analysis revealed that cleavage of recombinant SPLUNC1-Δ19 by neutrophil elastase indeed 
resulted in the formation of peptides corresponding to the S18 region (Figure 9C and Table 1), 
suggesting that release of this region may be a mechanism to make the ENaC inhibitory domain 
of SPLUNC1 more available during times of inflammation, i.e. when both SPLUNC1 and 
neutrophil elastase levels are increased.  This release of a S18-like region may serve to inhibit 
ENaC, increase hydration of the mucus layer and increase mucus clearance which would be 
beneficial for innate lung defense.  Interestingly, similar peptides to S18 were observed in 
normal human sputum samples but were undetectable in CF sputum.  While this may suggest 
that endogenous S18-type peptides are formed in normal ASL, whether they are present at 
sufficient concentration to regulate ENaC in vivo remains to be determined. Free neutrophil 
elastase is absent from the lungs of healthy individuals.  However, the peptides that we detected 
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may arise from the normal breakdown of SPLUNC1 by the extracellular proteases which are 
present in the airways (30).   
SPLUNC1 is detectable in CF HBEC ASL (21)(Fig. 7B) and may even be upregulated in 
CF airways, (5, 41).  However, we do not detect autoregulation of ENaC in CF HBECs (46).  CF 
airways are moderately acidic due to the lack of bicarbonate secretion through CFTR(16).  We 
have recently demonstrated that SPLUNC1 fails to function in the acidic environment seen in CF 
ASL due to pH-sensitive conformation changes in SPLUNC1 which reduce SPLUNC1-ENaC 
interactions (21).  This is likely due to pH-sensitive regions on the main SPLUNC1 protein and 
the S18 peptide alone is pH-independent (21).  Consistent with this observation, we found that 
S18 inhibited Na+/ASL absorption in CF HBECs for >24 h following a single dose. This long 
duration of action may be due to the ability of S18 to bind directly to -ENaC, unlike the small 
molecule inhibitor amiloride, which is rapidly transported across the epithelia and has a half-life 
in the ASL of 10 min (45). Furthermore, we speculate that since S18 binds to -ENaC, that it 
will not be actively transported across the airways, and would avoid the off-target effects seen 
with amiloride and its analogues, such as inhibition of ENaC in the kidneys which can lead to 
natriuresis and reduced blood pressure. In summary, S18 is heat-stable, protease-resistant and 
inhibits ENaC/ASL hyperabsorption for up to 24 h in CF HBECs, suggesting that it has 
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FIGURE 1. Identification of SPLUNC1’s ENaC inhibitory domain.  A) Normal HBECs were 
exposed to 100 M bumetanide serosally and then Vt was measured immediately before (t=0) 
and at timed intervals after exposure to vehicle (20 l Ringer alone), 30 M 19 SPLUNC1, S18 
or ADG in 20 l Ringer.  After 60 min, 100 M amiloride was added mucosally as a dry powder 
in perfluorocarbon and Vt was remeasured 20 min later.  N.B., amiloride significantly (p<0.05) 
decreased Vt in vehicle and ADG-exposed but not S18- or SPLUNC1
19 exposed HBECs 
(statistical symbols omitted for clarity).   B) The amiloride-sensitive Vt was measured in normal 
HBECs after 1 h exposure to vehicle (20 l Ringer) or Ringer containing 30 M of S18 from 







FIGURE 2.  S18 inhibits ENaC currents in the Xenopus oocyte expression system.  A) The 
effect of 10 and 100 μM S18 on the amiloride-sensitive ENaC current.    B) The effect of 
MTSET on the amiloride-sensitive ENaC current in the presence or absence of 10 or 100 μM 
S18.  C) The effect of 10 and 100 μM ADG on the amiloride-sensitive ENaC current. *, p < 0.05 
different from vehicle or non-transfected currents as appropriate.  † p < 0.05 different from S18.  
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FIGURE 3. Acute S18 peptide exposure does not affect the function of ASIC1a, ASIC2a 
and ASIC3. Whole-cell currents were measured from CHO cells stably expressing ASIC 
subunits, voltage clamped to -60 mV.  Stimulations lasted 5 s and were performed every 45 s. A) 
A typical experiment with an ASIC1a-expressing cell is shown. Cells were stimulated three 
times with pH 6.6 (ASIC1a and -3) or pH 4 (ASIC2a). Between stimulations, cells were returned 
to a pH 7.4 conditioning solution for 40 s to allow recovery from inactivation. The conditioning 
solution was then switched to a pH 7.4 solution containing 10 µM S18. Three stimulations in the 
presence of 10 µM S18 were performed before washing off the peptide. B) Current amplitudes of 
the above described experiments were normalized to the first control value and plotted as a 
function of time. S18 was added at T = 0 s.  ASIC1a = ■, ASIC2a = ●, ASIC3 = ▲, all  n = 3. C) 
Cells were incubated for 40 s in a pH 7.1 (ASIC1a and -3) or 5.6 (ASIC2a) conditioning 
solution, then activated using an acidic stimulus (pH 5 for ASIC1a and -3, and pH 4 for 
ASIC2a). Experiments were performed with or without 10 µM S18 in the conditioning solution. 
Current amplitudes measured during the acidic stimulus were normalized to the control 
amplitude obtained with a pH 7.4 conditioning solution.  Open bars = control, closed bars = S18, 
all n = 3-4. D) Cells expressing ASIC1a were stimulated three times with a pH 6.6 stimulus 
before 40 µg/ml trypsin was added to the pH 7.4 solution. Stimulations were performed every 45 
s. The protocol was performed with or without 10 µM S18 in all solutions. The average current is 




FIGURE 4. 1 h S18 peptide exposure stimulates ASIC2a. CHO cells stably expressing ASIC 
subunits were exposed to vehicle (Ringer, open bars) or S18 (10 M, closed bars) for 1 h. 
Voltage was clamped to -60 mV and whole-cell currents were measured.  ASIC1a, n=7. ASIC2a, 






FIGURE 5. Analysis of S18-ENaC Interactions.  A) Typical western blot of the triple-
transfected αβγ-ENaC peptide pull-down assay.  The pull-down assay was performed with one 
V5-tagged subunit and two untagged subunits as designated.  B) Typical western blot of the S18 
peptide pull-down assay of individually expressed ENaC subunits. IN = input, PD = pull-down 
elution.  C) Typical western blot showing the pull-down assay performed with S18 or ADG.  No 
β-ENaC was observed in the elution with the ADG peptide confirming that the observed β -
























FIGURE 6. The β-ENaC/S18 interaction is glycosylation dependent in HEK293T cells.  A) 
Typical western blot of the αβγ-ENaC peptide pull-down assay with the β-ENaC subunit V5-
tagged and untagged α and γ-ENaC subunits.  The pull-down assay was performed and the 
elution treated with EndoH.  B) Typical western blot of the β-ENaC only peptide pull-down 
assay with the β-ENaC subunit V5-tagged.  The pull-down assay was performed and the elution 
treated with EndoH.  C) Typical western blot of the tunicamycin pre-treated β-ENaC pull-down 
assay when cells were co-transfected with V5-tagged β-ENaC and untagged α and γ-ENaC 
subunits.  D) Typical blot of the tunicamycin pre-treated β-ENaC pull-down assay when cells 






















FIGURE 7. S18 inhibits CF ASL hyperabsorption.  A) Confocal micrographs of normal and 
CF ASL height 24 h after exposure to S18 or vehicle (control). Scale bar  = 7 μm.  B) Mean ASL 
height over time in normal and CF HBECs with or without addition of S18; dashed lines are 
normal HBECs (ctrl =▲, S18 = ●), non-dashed lines are CF HBECs (ctrl = ♦, S18 = ■), n = 6; *, 
p < 0.05 different from basal. Inset: Typical slot blot for SPLUNC1 lavaged from the mucosal 
surfaces of  normal and CF HBECs at timed intervals.  Mucosal surfaces were left undisturbed 
for 24 h, washed immediately prior to initiating ASL height experiments, and in parallel cultures, 
subsequent SPLUNC1 recovery was determined.   C) Change in ASL height with increasing 
concentration of S18 in normal (closed) and CF (open) HBECs.  D) Thin film transepithelial PD 
for normal HBECs. Open bars = control, closed bars = S18, n = 10.  E) Thin film transepithelial 
PD for CF HBECs. Open bars = control, closed bars = S18, n = 6. F) ASL height over time in 
normal HBECs in the presence of 100 μM bumetanide with (■) or without S18 (♦), n = 6.  * = 






FIGURE 8. S18 maintains ASL height of CF HBECs with no intrinsic structure.  A) Far-
UV CD spectra of S18 at 25°C.  B) ASL height of CF HBECs at 2 h.  Control = open bar, S18 at 








FIGURE 9. S18 prevents ASL hyperabsorption in the presence of neutrophil elastase.  A, 
B, Bargraphs of ASL height at 8 h in CF HBECs. A) Control (open bar), 100 M S18 (black 
bars), and 10 M aprotinin (gray bars). NE = neutrophil elastase, APROT = aprotinin, ANS = 
activated neutrophil supernatant.  NE was added at 100 nM.  ANS was diluted 1:1 with PBS.  All 
n = 6.  * p < 0.05 different to control. † p < 0.05 different to aprotinin.  B) Bargraph of ASL 
height in CF HBECs at 8 h. Control (open bar), 100 M S18 with 100 nM NE with or without 
ONO (black bars), and 10 M ONO (gray bar).  All n = 6.  * p < 0.05 different to control.  C) 
Sequence of SPLUNC1 obtained by mass spectrometry with the observed residues after 5 min 




TABLE 1. Peptides observed by mass spectrometry in the neutrophil elastase 5-min cleavage assay 
of 19-SPLUNC1- 
Residue  Sequence Residue Sequence 
23-45 GLPVPLDQTLPLNVNPALPLSPT 122-131 QSPDGHRLYV 
27-45 PLDQTLPLNVNPALPLSPT 123-131 SPDGHRLYV 
32-45 LPLNVNPALPLSPT 124-131 PDGHRLYV 
46-61 GLAGSLTNALSNGLLS 125-131 DGHRLYV 
46-67 GLAGSLTNALSNGLLSGGLLGI 132-141 TIPLGIKLQV 
46-86 GLAGSLTNALSNGLLSGGLLGILENLPLLDILKPGGGTSGG 132-148 TIPLGIKLQVNTPLVGA 
53-86 NALSNGLLSGGLLGILENLPLLDILKPGGGTSGG 132-155 TIPLGIKLQVNTPLVGASLLRLAV 
53-95 NALSNGLLSGGLLGILENLPLLDILKPGGGTSGGLLGGLLGKV 138-148 KLQVNTPLVGA 
53-96 NALSNGLLSGGLLGILENLPLLDILKPGGGTSGGLLGGLLGKVT 138-149 KLQVNTPLVGAS 
54-95 ALSNGLLSGGLLGILENLPLLDILKPGGGTSGGLLGGLLGKV 138-151 KLQVNTPLVGASLL 
62-95 GGLLGILENLPLLDILKPGGGTSGGLLGGLLGKV 142-155 NTPLVGASLLRLAV 
62-96 GGLLGILENLPLLDILKPGGGTSGGLLGGLLGKVT 149-155 SLLRLAV 
67-95 ILENLPLLDILKPGGGTSGGLLGGLLGKV 156-166 KLDITAEILAV 
68-95 LENLPLLDILKPGGGTSGGLLGGLLGKV 156-173 KLDITAEILAVRDKQERI 
74-86 LDILKPGGGTSGG 160-173 TAEILAVRDKQERI 
77-95 LKPGGGTSGGLLGGLLGKV 164-173 LAVRDKQERI 
77-96 LKPGGGTSGGLLGGLLGKVT 165-172 AVRDKQER 
84-95 SGGLLGGLLGKV 165-173 AVRDKQERI 
84-96 SGGLLGGLLGKVT 166-173 VRDKQERI 
87-95 LLGGLLGKV 201-219 QGLLDSLTGILNKVLPELV 
87-96 LLGGLLGKVT 231-236 LRGLDI 
106-131 IDIKVTDPQLLELGLVQSPDGHRLYV 231-239 LRGLDITLV 
107-118 DIKVTDPQLLEL 231-243 LRGLDITLVHDIV 
107-121 DIKVTDPQLLELGLV 231-247 LRGLDITLVHDIVNMLI 
107-131 DIKVTDPQLLELGLVQSPDGHRLYV 237-247 TLVHDIVNMLI 
109-118 KVTDPQLLEL 240-247 HDIVNMLI 
109-121 KVTDPQLLELGLV 240-256 HDIVNMLIHGLQFVIKV 
109-131 KVTDPQLLELGLVQSPDGHRLYV 248-253 HGLQFV 
111-131 TDPQLLELGLVQSPDGHRLYV 248-254 HGLQFVI 
119-131 GLVQSPDGHRLYV 248-256 HGLQFVIKV 
121-131 VQSPDGHRLYV   
 
 
 
 
 
 
 
 
 
 
